Heparan sulfate and heparanase as modulators of breast cancer progression

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Gomes, Angélica M ^a   Stelling, Mariana P ^a   Pavão, Mauro S G ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHONDROITIN SULFATE; DECORIN; DERMATAN SULFATE; DNA TOPOISOMERASE; DOCETAXEL; ENZYME INHIBITOR; ESTROGEN RECEPTOR; GLYCOSAMINOGLYCAN POLYSULFATE; GLYPICAN 3; HEPARAN SULFATE; HEPARANASE; HEPARANASE INHIBITOR; PADGEM PROTEIN; PI 88; PROTEOHEPARAN SULFATE; SYNDECAN 1; SYNDECAN 2; SYNDECAN 4; UNCLASSIFIED DRUG; VASCULOTROPIN; BETA GLUCURONIDASE;

APOPTOSIS; BONE METASTASIS; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CELL ADHESION; CELL DEATH; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; CELL SURFACE; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; MENSTRUAL CYCLE; METASTASIS; NONHUMAN; OSTEOCLAST ACTIVITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SULFATION; TUMOR VASCULARIZATION; BIOLOGICAL MODEL; BREAST TUMOR; CHEMISTRY; DISEASE COURSE; ENZYMOLOGY; FEMALE; METABOLISM; PATHOLOGY;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS;

EID: 84883164877     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/852093     Document Type: Review

References (103)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010. CA Cancer Journal for Clinicians 2010 60 5 277 300 2-s2.0-77955635233 10.3322/caac.20073
2. Sarrazin S., Lamanna W. C., Esko J. D., Heparan sulfate proteoglycans. Cold Spring Harbor perspectives in biology 2011 3 7 2-s2.0-80455173449
3. Barbareschi M., Maisonneuve P., Aldovini D., Cangi M. G., Pecciarini L., Mauri F. A., Veronese S., Caffo O., Lucenti A., Palma P. D., Galligioni E., Doglioni C., High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003 98 3 474 483 2-s2.0-0037962017 10.1002/cncr.11515
4. Matsuda K., Maruyama H., Guo F., Kleeff J., Itakura J., Matsumoto Y., Lander A. D., Korc M., Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Research 2001 61 14 5562 5569 2-s2.0-0035879011
5. Vlodavsky I., Beckhove P., Lerner I., Pisano C., Meirovitz A., Ilan N., Elkin M., Significance of heparanase in cancer and inflammation. Cancer Microenvironment 2012 5 2 115 132 2-s2.0-79960884703 10.1007/s12307-011-0082-7
6. Vlodavsky I., Elkin M., Abboud-Jarrous G., Levi-Adam F., Fuks L., Shafat I., Ilan N., Heparanase: one molecule with multiple functions in cancer progression. Connective Tissue Research 2008 49 3-4 207 210 2-s2.0-48549085133 10.1080/03008200802143281
7. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I., Spector L., Pecker I., Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nature Medicine 1999 5 7 793 802 2-s2.0-0033057962 10.1038/10518
8. Cohen I., Pappo O., Elkin M., San T., Bar-Shavit R., Hazan R., Peretz T., Vlodavsky I., Abramovitch R., Heparanase promotes growth, angiogenesis and survival of primary breast tumors. International Journal of Cancer 2006 118 7 1609 1617 2-s2.0-33644863802 10.1002/ijc.21552
9. Maxhimer J. B., Pesce C. E., Stewart R. A., Gattuso P., Prinz R. A., Xu X., Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. Journal of the American College of Surgeons 2005 200 3 328 335 2-s2.0-14544296126 10.1016/j.jamcollsurg. 2004.10.034
10. Raman K., Kuberan B., Chemical tumor biology of heparan sulfate proteoglycans. Current Chemical Biology 2010 4 1 20 31 2-s2.0-77950833141 10.2174/187231310790226206
11. Dedes P. G., Gialeli C., Tsonis A. I., Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochimica et Biophysica Acta 2012 1820 12 1926 1939 10.1016/j.bbagen.2012.07.013
12. Malavaki C. J., Roussidis A. E., Gialeli C., Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells. FEBS Journal 2013 280 2477 2489
13. Watson C. J., Khaled W. T., Mammary development in the embryo and adult: a journey of morphogenesis and commitment. Development 2008 135 6 995 1003 2-s2.0-42549142931 10.1242/dev.005439
14. Delehedde M., Lyon M., Sergeant N., Rahmoune H., Fernig D. G., Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. Journal of Mammary Gland Biology and Neoplasia 2001 6 3 253 273 2-s2.0-0035405257 10.1023/A:1011367423085
15. Prince J. M., Klinowska T. C. M., Marshman E., Lowe E. T., Mayer U., Miner J., Aberdam D., Vestweber D., Gusterson B., Streuli C. H., Cell-matrix interactions during development and apoptosis of the mouse mammary gland in vivo. Developmental Dynamics 2002 223 4 497 516 2-s2.0-18344394642 10.1002/dvdy.10070
16. Zako M., Dong J., Goldberger O., Bernfield M., Gallagher J. T., Deakins J. A., Syndecan-1 and -4 synthesized simultaneously by mouse mammary gland epithelial cells bear heparan sulfate chains that are apparently structurally indistinguishable. Journal of Biological Chemistry 2003 278 15 13561 13569 2-s2.0-0037968622 10.1074/jbc.M209658200
17. Deepa S. S., Yamada S., Zako M., Goldberger O., Sugahara K., Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors: a novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor. Journal of Biological Chemistry 2004 279 36 37368 37376 2-s2.0-4444347398 10.1074/jbc.M403031200
18. Hallberg G., Andersson E., Naessén T., Ordeberg G. E., The expression of syndecan-1, syndecan-4 and decorin in healthy human breast tissue during the menstrual cycle. Reproductive Biology and Endocrinology 2010 8, article 35 2-s2.0-77950830267 10.1186/1477-7827-8-35
19. Xiang Y.-Y., Ladeda V., Filmus J., Glypican-3 expression is silenced in human breast cancer. Oncogene 2001 20 50 7408 7412 2-s2.0-0035504922 10.1038/sj.onc.1204925
20. Garner O. B., Bush K. T., Nigam K. B., Yamaguchi Y., Xu D., Esko J. D., Nigam S. K., Stage-dependent regulation of mammary ductal branching by heparan sulfate and HGF-cMet signaling. Developmental Biology 2011 355 2 394 403 2-s2.0-80955180209 10.1016/j.ydbio.2011.04.035
21. Bush K. T., Crawford B. E., Garner O. B., N-sulfation of heparan sulfate regulates early branching events in the developing mammary gland. The Journal of Biological Chemistry 2012 287 42064 42070
22. Crawford B. E., Garner O. B., Bishop J. R., Zhang D. Y., Bush K. T., Nigam S. K., Esko J. D., Loss of the heparan sulfate sulfotransferase, Ndst1, in mammary epithelial cells selectively blocks lobuloalveolar development in mice. PLoS ONE 2010 5 5 2-s2.0-77955278541 10.1371/journal.pone.0010691 e10691
23. Ferguson J. E., Schor A. M., Howell A., Ferguson M. W. J., Changes in the extracellular matrix of the normal human breast during the menstrual cycle. Cell and Tissue Research 1992 268 1 167 177 2-s2.0-0026535130
24. Yoneda A., Lendorf M. E., Couchman J. R., Multhaupt H. A. B., Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. Journal of Histochemistry and Cytochemistry 2012 60 1 9 21 2-s2.0-84856637517 10.1369/0022155411428469
25. Götte M., Kersting C., Radke I., Kiesel L., Wülfing P., An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Research 2007 9 1, article R8 2-s2.0-34248212890 10.1186/bcr1641
26. Koo C.-Y., Bay B.-H., Lui P. C.-W., Tse G. M.-K., Tan P.-H., Yip G. W.-C., Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors. Modern Pathology 2006 19 10 1344 1350 2-s2.0-33748857960 10.1038/modpathol.3800657
27. Baba F., Swartz K., Van Buren R., Eickhoff J., Zhang Y., Wolberg W., Friedl A., Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Research and Treatment 2006 98 1 91 98 2-s2.0-33745898538 10.1007/s10549-005- 9135-2
28. Leivonen M., Lundin J., Nordling S., Von Boguslawski K., Haglund C., Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004 67 1 11 18 2-s2.0-5644277510 10.1159/000080280
29. Barbareschi M., Maisonneuve P., Aldovini D., Cangi M. G., Pecciarini L., Mauri F. A., Veronese S., Caffo O., Lucenti A., Palma P. D., Galligioni E., Doglioni C., High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003 98 3 474 483 2-s2.0-0037962017 10.1002/cncr.11515
30. Fernández-Vega I., García O., Crespo A., Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer. BMC Cancer 2013 13, article 24
31. Koo C.-Y., Sen Y.-P., Bay B.-H., Yip G. W., Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Patents on Anti-Cancer Drug Discovery 2008 3 3 151 158 2-s2.0-58049215512 10.2174/157489208786242278
32. Guo C.-H., Koo C.-Y., Bay B.-H., Tan P.-H., Yip G. W., Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour. International Journal of Oncology 2007 31 6 1415 1423 2-s2.0-38449089309
33. Eshchenko T. Y., Rykova V. I., Chernakov A. E., Sidorov S. V., Grigorieva E. V., Expression of different proteoglycans in human breast tumors. Biochemistry 2007 72 9 1016 1020 2-s2.0-34948872542 10.1134/S0006297907090143
34. Mitropoulou T. N., Tzanakakis G. N., Nikitovic D., Tsatsakis A., Karamanos N. K., In vitro effects of genistein on the synthesis and distribution of glycosaminoglycans / proteoglycans by estrogen receptor-positive and -negative human breast cancer epithelial cells. Anticancer Research 2002 22 5 2841 2846 2-s2.0-0036765669
35. Mitropoulou T. N., Theocharis A. D., Nikitovic D., Karamanos N. K., Tzanakakis G. N., IGF-I affects glycosaminoglycan/proteoglycan synthesis in breast cancer cells through tyrosine kinase-dependent and -independent pathways. Biochimie 2004 86 4-5 251 259 2-s2.0-2942640103 10.1016/j.biochi.2004.04.008
36. Tsonis A. I., Afratis N., Gialeli C., Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells. FEBS Journal 2013 280 2248 2259
37. Kousidou O. C., Berdiaki A., Kletsas D., Zafiropoulos A., Theocharis A. D., Tzanakakis G. N., Karamanos N. K., Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Molecular Oncology 2008 2 3 223 232 2-s2.0-51449094588 10.1016/j.molonc.2008.06.002
38. Hassan H., Greve B., Pavao M. S. G., Kiesel L., Ibrahim S. A., Götte M., Syndecan-1 modulates β -integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS Journal 2013 280 10 2216 227 10.1111/febs.12111
39. Maeda T., Desouky J., Friedl A., Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006 25 9 1408 1412 2-s2.0-33644764714 10.1038/sj.onc.1209168
40. Maeda T., Alexander C. M., Friedl A., Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Research 2004 64 2 612 621 2-s2.0-1642515775 10.1158/0008-5472.CAN-03- 2439
41. Stanley M. J., Stanley M. W., Sanderson R. D., Zera R., Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. American Journal of Clinical Pathology 1999 112 3 377 383 2-s2.0-0033491136
42. Buchanan C., Stigliano I., Garay-Malpartida H. M., Rodrigues Gomes L., Puricelli L., Sogayar M. C., Bal De Kier Joffé E., Peters M. G., Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways. Breast Cancer Research and Treatment 2010 119 3 559 574 2-s2.0-74849095019 10.1007/s10549-009-0362-9
43. Xu C., Yan Z., Zhou L., Wang Y., A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. Journal of Cancer Research and Clinical Oncology 2013 139 1417 1424
44. Fu S.-J., Qi C.-Y., Xiao W.-K., Li S.-Q., Peng B.-G., Liang L.-J., Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. 2013. Surgery 10.1016/j.surg.2013.02.014
45. Nerlich A. G., Wiest I., Wagner E., Sauer U., Schleicher E. D., Gene expression and protein deposition of major basement membrane components and TGF- β 1 in human breast cancer. Anticancer Research 1997 17 6 D 4443 4449 2-s2.0-0031425495
46. Su G., Blaine S. A., Qiao D., Friedl A., Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. Journal of Biological Chemistry 2007 282 20 14906 14915 2-s2.0-34447500705 10.1074/jbc.M611739200
47. Mundhenke C., Meyer K., Drew S., Friedl A., Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. American Journal of Pathology 2002 160 1 185 194 2-s2.0-0036144193
48. Wang Z., Xu Y., Yang B., Tirachinapally G., Sun B., Liu R., Dulaney S., Liu J., Huang X., Preactivation-based, one-pot combinatorial synthesis of heparin-like hexasaccharides for the analysis of heparin-protein interactions. Chemistry 2010 16 28 8365 8375 2-s2.0-77954853474 10.1002/chem.201000987
49. Nurcombe V., Smart C. E., Chipperfield H., Cool S. M., Boilly B., Hondermarck H., The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. Journal of Biological Chemistry 2000 275 39 30009 30018 2-s2.0-0034730725
50. Fernig D. G., Chen H.-L., Rahmoune H., Descamps S., Boilly B., Hondermarck H., Differential regulation of FGF-1 and -2 mitogenic activity is related to their kinetics of binding to heparan sulfate in MDA-MB-231 human breast cancer cells. Biochemical and Biophysical Research Communications 2000 267 3 770 776 2-s2.0-0034719464 10.1006/bbrc.1999.2028
51. Delehedde M., Deudon E., Boilly B., Hondermarck H., Production of sulfated proteoglycans by human breast cancer cell lines: binding to fibroblast growth factor-2. Journal of Cellular Biochemistry 1997 64 605 617
52. Delehedde M., Deudon E., Boilly B., Hondermarck H., Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity in human breast cancer cells. Experimental Cell Research 1996 229 2 398 406 2-s2.0-0030589657 10.1006/excr.1996.0385
53. Kato M., Saunders S., Nguyen H., Bernfield M., Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Molecular Biology of the Cell 1995 6 5 559 576 2-s2.0-0029005076
54. Nikolova V., Koo C.-Y., Ibrahim S. A., Wang Z., Spillmann D., Dreier R., Kelsch R., Fischgräbe J., Smollich M., Rossi L. H., Sibrowski W., Wülfing P., Kiesel L., Yip G. W., Götte M., Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009 30 3 397 407 2-s2.0-62349114465 10.1093/carcin/bgp001
55. Yang Y., MacLeod V., Miao H.-Q., Theus A., Zhan F., Shaughnessy J. D. Jr., Sawyer J., Li J.-P., Zcharia E., Vlodavsky I., Sanderson R. D., Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. Journal of Biological Chemistry 2007 282 18 13326 13333 2-s2.0-34250366643 10.1074/jbc.M611259200
56. Sanderson R. D., Yang Y., Suva L. J., Kelly T., Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biology 2004 23 6 341 352 2-s2.0-7944230119 10.1016/j.matbio.2004.08.004
57. Ding K., Lopez-Burks M., Sánchez-Duran J. A., Korc M., Lander A. D., Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. Journal of Cell Biology 2005 171 4 729 738 2-s2.0-27944469616 10.1083/jcb.200508010
58. Mi D., Gao Y., Zheng S., Ba X., Zeng X., Inhibitory effects of chemically modified heparin on the P-selectin-mediated adhesion of breast cancer cells in vitro. Molecular Medicine Reports 2009 2 2 301 306 2-s2.0-69249106020 10.3892/mmr-00000100
59. Mellor P., Harvey J. R., Murphy K. J., Pye D., O'Boyle G., Lennard T. W. J., Kirby J. A., Ali S., Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. British Journal of Cancer 2007 97 6 761 768 2-s2.0-34548585134 10.1038/sj.bjc.6603928
60. Peters M. G., Farías E., Colombo L., Filmus J., Puricelli L., Bal De Kier Joffé E., Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Research and Treatment 2003 80 2 221 232 2-s2.0-0037660828 10.1023/A:1024549729256
61. Dedes P. G., Kanakis I., Gialeli C., Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease. Biochimica et Biophysica Acta 2013 1830 3625 3634
62. Khurana A., Beleford D., He X., Chien J., Shridhar V., Role of heparan sulfatases in ovarian and breast cancer. American Journal of Cancer Research 2013 3 34 45
63. Lai J., Chien J., Staub J., Avula R., Greene E. L., Matthews T. A., Smith D. I., Kaufmann S. H., Roberts L. R., Shridhar V., Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. Journal of Biological Chemistry 2003 278 25 23107 23117 2-s2.0-0038677717 10.1074/jbc.M302203200
64. Narita K., Staub J., Chien J., Meyer K., Bauer M., Friedl A., Ramakrishnan S., Shridhar V., HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Research 2006 66 12 6025 6032 2-s2.0-33745728172 10.1158/0008-5472.CAN-05-3582
65. Morimoto-Tomita M., Uchimura K., Bistrup A., Lum D. H., Egeblad M., Boudreau N., Werb Z., Rosen S. D., Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005 7 11 1001 1010 2-s2.0-33644658017 10.1593/neo.05496
66. Khurana A., Jung-Beom D., He X., Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts. Clinical and Experimental Metastasis 2013 30 4 407 415 10.1007/s10585-012-9546-5
67. Bret C., Moreaux J., Schved J.-F., Hose D., Klein B., SULFs in human neoplasia: implication as progression and prognosis factors. Journal of Translational Medicine 2011 9, article 72 2-s2.0-79956226810 10.1186/1479-5876-9-72
68. Peterson S. M., Iskenderian A., Cook L., Romashko A., Tobin K., Jones M., Norton A., Gómez-Yafal A., Heartlein M. W., Concino M. F., Liaw L., Martini P. G. V., Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts. BMC Cancer 2010 10, article 427 2-s2.0-77955488762 10.1186/1471-2407-10-427
69. Franses J. W., Baker A. B., Chitalia V. C., Edelman E. R., Stromal endothelial cells directly influence cancer progression. Science Translational Medicine 2011 3 66 2-s2.0-78751656154 10.1126/scitranslmed.3001542 66ra5
70. Theodoro T. R., de Matos L. L., Anna A. V. L. S., Fonseca F. L. A., Semedo P., Martins L. C., Nader H. B., Del Giglio A., Pinhal M. A. D. S., Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia 2007 9 6 504 510 2-s2.0-34250904128 10.1593/neo.07241
71. Su G., Blaine S. A., Qiao D., Friedl A., Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Research 2008 68 22 9558 9565 2-s2.0-56449115869 10.1158/0008-5472.CAN-08-1645
72. Terp M. G., Lund R. R., Jensen O. N., Leth-Larsen R., Ditzel H. J., Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics. Cancer Genomics Proteomics 2012 9 5 265 273
73. Svensson K. J., Christianson H. C., Paulina K., Victor F., Lars L., Signe B., Karin J., Belting M., Chondroitin sulfate expression predicts poor outcome in breast cancer. International Journal of Oncology 2011 39 6 1421 1428 2-s2.0-80054804895 10.3892/ijo.2011.1164
74. Cooney C. A., Jousheghany F., Yao-Borengasser A., Phanavanh B., Gomes T., Kieber-Emmons A. M., Siegel E. R., Suva L. J., Ferrone S., Kieber-Emmons T., Monzavi-Karbassi B., Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Research 2011 13 3, article R58 2-s2.0-84860390514 10.1186/bcr2895
75. Monzavi-Karbassi B., Stanley J. S., Hennings L., Jousheghany F., Artaud C., Shaaf S., Kieber-Emmons T., Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. International Journal of Cancer 2007 120 6 1179 1191 2-s2.0-33847058472 10.1002/ijc.22424
76. Prinz R. D., Willis C. M., Viloria-Petit A., Klüppel M., Elimination of breast tumor-associated chondroitin sulfate promotes metastasis. Genetics and Molecular Research 2011 10 3901 3913
77. Rykova V. I., Grigorieva E. V., Chernenko A. V., Eshenko T. Y., Dymshits G. M., Proteoglycans and human breast cancer. Bulletin of Experimental Biology and Medicine 2007 144 3 335 337 2-s2.0-37749042026 10.1007/s10517-007-0326-1
78. Alini M., Losa G. A., Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues. Cancer Research 1991 51 5 1443 1447 2-s2.0-0025756555
79. Vijayagopal P., Figueroa J. E., Levine E. A., Altered composition and increased endothelial cell proliferative activity of proteoglycans isolated from breast carcinoma. Journal of Surgical Oncology 1998 68 250 254
80. De Lima C. R., de Arimatéa dos Santos Junior J., Nazário A. C. P., Michelacci Y. M., Changes in glycosaminoglycans and proteoglycans of normal breast and fibroadenoma during the menstrual cycle. Biochimica et Biophysica Acta 2012 1820 1009 1019
81. Vlodavsky I., Elkin M., Ilan N., Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applications. Rambam Maimonides Medical Journal 2011 2 e0019
82. Vlodavsky I., Miao H.-Q., Benezra M., Involvement of the extracellular matrix, heparan sulphate proteoglycans, and heparan sulphate degrading enzymes in angiogenesis and metastasis. Tumor Angiogenesis 1997 Oxford, UK Oxford University Press 125 140
83. Edovitsky E., Elkin M., Zcharia E., Peretz T., Vlodavsky I., Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. Journal of the National Cancer Institute 2004 96 16 1219 1230 2-s2.0-4344598247 10.1093/jnci/djh230
84. Zhang L., Sullivan P., Suyama J., Marchetti D., Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Molecular Cancer Research 2010 8 2 278 290 2-s2.0-77249112379 10.1158/1541-7786.MCR-09-0375
85. Pagel J.-I., Deindl E., Early growth response 1-a transcription factor in the crossfire of signal transduction cascades. Indian Journal of Biochemistry and Biophysics 2011 48 4 226 235 2-s2.0-80052868490
86. Kelly T., Suva L. J., Huang Y., MacLeod V., Miao H.-Q., Walker R. C., Sanderson R. D., Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Research 2005 65 13 5778 5784 2-s2.0-21344452789 10.1158/0008-5472.CAN-05-0749
87. De Mestre A. M., Rao S., Hornby J. R., Soe-Htwe T., Khachigian L. M., Hulett M. D., Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. Journal of Biological Chemistry 2005 280 42 35136 35147 2-s2.0-27444442647 10.1074/jbc.M503414200
88. Cohen I., Maly B., Simon I., Meirovitz A., Pikarsky E., Zcharia E., Peretz T., Vlodavsky I., Elkin M., Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer. Clinical Cancer Research 2007 13 14 4069 4077 2-s2.0-34547121192 10.1158/1078-0432.CCR-06-2546
89. Done S. J., Eskandarian S., Bull S., Redston M., Andrulis I. L., P53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. Journal of the National Cancer Institute 2001 93 9 700 704 2-s2.0-0035795630
90. Baraz L., Haupt Y., Elkin M., Peretz T., Vlodavsky I., Tumor suppressor p53 regulates heparanase gene expression. Oncogene 2006 25 28 3939 3947 2-s2.0-33745606964 10.1038/sj.onc.1209425
91. Lu W. C., Liu Y. N., Kang B. B., Chen J. H., Trans-activation of heparanase promoter by ETS transcription factors. Oncogene 2003 22 6 919 923 2-s2.0-0037434721 10.1038/sj.onc.1206201
92. Folkman J., Klagsbrun M., Sasse J., Wadzinski M., Ingber D., Vlodavsky I., A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. American Journal of Pathology 1988 130 2 393 400 2-s2.0-0023831047
93. Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I., Ilan N., Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Research 2006 66 3 1455 1463 2-s2.0-32944479184 10.1158/0008-5472.CAN-05-1811
94. Imada T., Matsuoka J., Nobuhisa T., Okawa T., Murata T., Tabuchi Y., Shirakawa Y., Ohara N., Gunduz M., Nagatsuka H., Umeoka T., Yamamoto Y., Nakajima M., Tanaka N., Naomoto Y., COX-2 induction by heparanase in the progression of breast cancer. International Journal of Molecular Medicine 2006 17 2 221 228 2-s2.0-33644854118
95. Zhang L., Sullivan P. S., Goodman J. C., Gunaratne P. H., Marchetti D., MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Research 2011 71 3 645 654 2-s2.0-79551514024 10.1158/0008-5472.CAN-10- 1910
96. Dredge K., Hammond E., Handley P., Gonda T. J., Smith M. T., Vincent C., Brandt R., Ferro V., Bytheway I., PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. British Journal of Cancer 2011 104 4 635 642 2-s2.0-79951676056 10.1038/bjc.2011.11
97. Hammond E., Brandt R., Dredge K., PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS ONE 2012 7 e52175
98. Parish C. R., Freeman C., Brown K. J., Francis D. J., Cowden W. B., Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Research 1999 59 14 3433 3441 2-s2.0-0033565247
99. Miao H. Q., Elkin M., Aingorn E., Ishai-Michaeli R., Stein C. A., Vlodavsky I., Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. International Journal of Cancer 1999 83 424 431
100. Cai Y.-G., Fang D.-C., Chen L., Tang X.-D., Chen T., Yu S.-T., Luo Y.-H., Xiong Z., Wang D.-X., Yang S.-M., Dendritic cells reconstituted with a human heparanase gene induce potent cytotoxic T-cell responses against gastric tumor cells in vitro. Tumor Biology 2007 28 4 238 246 2-s2.0-34548474880 10.1159/000107584
101. Sommerfeldt N., Beckhove P., Ge Y., Schütz F., Choi C., Bucur M., Domschke C., Sohn C., Schneeweis A., Rom J., Pollmann D., Leucht D., Vlodavsky I., Schirrmacher V., Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Research 2006 66 15 7716 7723 2-s2.0-33747890807 10.1158/0008-5472.CAN-05-2363
102. Wang G.-Z., Tang X.-D., Lü M.-H., Gao J.-H., Liang G.-P., Li N., Li C.-Z., Wu Y.-Y., Chen L., Cao Y.-L., Fang D.-C., Yang S.-M., Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors. Cancer Prevention Research 2011 4 8 1285 1295 2-s2.0-80051496177 10.1158/1940-6207.CAPR-11-0083
103. Barcellos-Hoff M. H., Lyden D., Wang T. C., The evolution of the cancer niche during multistage carcinogenesis. Nature Reviews Cancer 2013 13 511 518